New Enterprise Associates

Latest Headlines

Latest Headlines

NEA backs $14M round for a biotech startup focused on autism disorder

New Enterprise Associates has stepped up to help with a $14 million A round designed to get Austin, TX-based startup Lumos Pharmaceuticals in the clinic with a new therapy for an autism spectrum disorder characterized by severe cognitive impairment.

One of biotech's top R&D chiefs makes the leap to the VC crowd at NEA

Elliott Sigal has opened the next chapter of his career. The former R&D chief at Bristol-Myers Squibb, who helped squire a number of blockbuster programs through the clinic, is joining David Mott as a venture partner at New Enterprise Associates.

NEA-backed orphan-drug accelerator bags another $10M

Cydan, an orphan-drug accelerator bankrolled by New Enterprise Associates and Pfizer Ventures, has secured another $10 million in venture cash.

Sanofi, NEA team up in $18M round for rare disease outfit Edimer

Edimer aims to use the new funds to bankroll a midstage study of its lead candidate EDI200, a recombinant protein intended to restore normal development in newborns with XLHED.

NEA backs Cartiva amid osteoarthritis trial

New Enterprise Associates (NEA) has dipped into its ample coffers to provide Cartiva with $4.3 million. The capital infusion backs the startup's ongoing clinical trial of a cartilage replacement implant in patients with osteoarthritis.

NEA's Mott, Kleiner Perkins pump $20M into cancer drug upstart

David Mott at New Enterprise Associates has put together a $20 million round to back 3-V Biosciences, an upstart biotech with deep roots in Switzerland's scientific community and an office in Silicon Valley.

Atlas Venture targets early-stage biotech bets with new $265M fund

After a period of revamping a venture strategy gone wrong, Atlas Venture has come out today with news about an oversubscribed 9 th fund of $265 million. It's a rare comeback story in a VC industry that is suffering from an overall lack of capital to fuel startups in biotech and other high-risk-and-reward sectors.

UPDATED: VC giant NEA backs Topera in $25M Series C

Topera first disclosed its $25 million Series C financing in a regulatory filing in March, but now it's revealing the investors behind the deal, and the lead one is a big fish indeed--New Enterprise Associates.

UPDATED: The Top 15 Biotech VC firms

Ask any biotech exec in the business of drug and device development about the funding environment these days, and you'll most likely hear the word "tough" inside of three seconds. The...

Pfizer Ventures backs effort to amp up orphan-drug development

David Mott, ex-CEO of MedImmune and a high-profile biotech partner at New Enterprise Associates, has led the way toward an orphan drug accelerator also backed by Pfizer Ventures.